Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,611.83
(
0.44%
)
US TECH 100
23,500.00
(
0.43%
)
Dow Jones
46,669.88
(
0.36%
)
Brent Oil
108.47
(
1.30%
)
Bitcoin
68,780.23
(
-0.11%
)
News Focus
News Focus
Post# of 257366
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122852
Boards Moderated 8
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 244871

Wednesday, 12/28/2022 1:50:29 PM

Wednesday, December 28, 2022 1:50:29 PM

Post# of 257366
The FDA-AMRN lawsuit settlement involved promotion for off-label indications. What we’re discussing vis-à-vis RVNC is the more limited question of a drugmaker’s using published clinical data in its promotion.

This NEJM article from 2009 is on-topic:
https://www.nejm.org/doi/10.1056/NEJMhle0807695

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now